Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Immix Biopharma (IMMX) has announced that Dr. Raymond Comenzo, an internationally recognized AL Amyloidosis expert, has joined the Scientific Advisory Board of its subsidiary Nexcella. Dr. Comenzo, Director of the Myeloma and Amyloid Program at Tufts Medical Center, is renowned for his pioneering work in developing consensus guidelines for clinical trials and response criteria in AL Amyloidosis. He was the senior author of the landmark Andromeda trial results, which led to the first FDA-approved therapy for AL amyloidosis.
Dr. Comenzo expressed excitement about joining Nexcella's efforts to advance CAR-T NXC-201 for treating relapsed/refractory AL Amyloidosis, an area with no currently approved drugs. Immix Biopharma's leadership believes Dr. Comenzo's expertise will greatly benefit their research and development efforts in this field.
Immix Biopharma (IMMX) ha annunciato che Dr. Raymond Comenzo, un esperto riconosciuto a livello internazionale di AL Amiloidosi, è entrato a far parte del Consiglio Scientifico della sua filiale Nexcella. Il Dr. Comenzo, Direttore del Programma sul Mieloma e l'Amiloide presso il Tufts Medical Center, è rinomato per il suo lavoro pionieristico nello sviluppo di linee guida di consenso per studi clinici e criteri di risposta nell'AL Amiloidosi. È stato l'autore principale dei risultati del fondamentale trial Andromeda, che ha portato alla prima terapia approvata dalla FDA per l'AL amiloidosi.
Il Dr. Comenzo ha espresso entusiasmo per l'ingresso negli sforzi di Nexcella per avanzare con CAR-T NXC-201 nel trattamento dell'AL Amiloidosi recidivante/refrattaria, un settore senza farmaci attualmente approvati. La leadership di Immix Biopharma crede che l'expertise del Dr. Comenzo apporterà grandi benefici ai loro sforzi di ricerca e sviluppo in questo campo.
Immix Biopharma (IMMX) ha anunciado que el Dr. Raymond Comenzo, un experto reconocido internacionalmente en amiloidosis AL, se ha unido al Consejo Asesor Científico de su filial Nexcella. El Dr. Comenzo, Director del Programa de Mieloma y Amiloide en el Tufts Medical Center, es conocido por su trabajo pionero en el desarrollo de guías de consenso para ensayos clínicos y criterios de respuesta en amiloidosis AL. Fue el autor principal de los resultados del revolucionario ensayo Andromeda, que condujo a la primera terapia aprobada por la FDA para la amiloidosis AL.
El Dr. Comenzo expresó su entusiasmo por unirse a los esfuerzos de Nexcella para avanzar en CAR-T NXC-201 en el tratamiento de la amiloidosis AL recidivante/refractaria, un área sin medicamentos actualmente aprobados. El liderazgo de Immix Biopharma cree que la experiencia del Dr. Comenzo beneficiará enormemente sus esfuerzos de investigación y desarrollo en este campo.
Immix Biopharma (IMMX)가 Dr. Raymond Comenzo가 국제적으로 인정받는 AL 아밀로이드증 전문가로서 자회사인 Nexcella의 과학 자문 위원회에 합류했다고 발표했습니다. Comenzo 박사는 Tufts Medical Center의 다발성 골수종 및 아밀로이드 프로그램의 소장으로서 AL 아밀로이드증의 임상 시험 및 반응 기준을 위한 합의 지침 개발에 대한 선구적인 작업으로 유명합니다. 그는 AL 아밀로이드증에 대한 최초의 FDA 승인 치료제로 이어진 획기적인 Andromeda 시험 결과의 수석 저자였습니다.
Comenzo 박사는 승인된 약물이 없는 분야에서 재발/불응성 AL 아밀로이드증 치료를 위한 CAR-T NXC-201 발전을 위한 Nexcella의 노력에 합류하게 되어 기대감을 표명했습니다. Immix Biopharma의 리더십은 Comenzo 박사의 전문성이 이 분야에서 그들의 연구 및 개발 노력에 크게 기여할 것이라고 믿고 있습니다.
Immix Biopharma (IMMX) a annoncé que Dr. Raymond Comenzo, un expert reconnu internationalement en amiloïdose AL, a rejoint le Conseil Consultatif Scientifique de sa filiale Nexcella. Dr. Comenzo, Directeur du Programme sur le Myélome et l'Amyloïde au Tufts Medical Center, est renommé pour son travail pionnier dans le développement de directives de consensus pour les essais cliniques et les critères de réponse en amiloïdose AL. Il a été l'auteur principal des résultats de l'essai Andromeda, qui a conduit à la première thérapie approuvée par la FDA pour l'amiloïdose AL.
Dr. Comenzo a exprimé son enthousiasme à rejoindre les efforts de Nexcella pour faire avancer CAR-T NXC-201 dans le traitement de l'amiloïdose AL récurrente/réfractaire, un domaine sans médicaments actuellement approuvés. La direction d'Immix Biopharma croit que l'expertise du Dr. Comenzo sera d'un grand avantage pour leurs efforts de recherche et développement dans ce domaine.
Immix Biopharma (IMMX) hat angekündigt, dass Dr. Raymond Comenzo, ein international anerkanntes AL-Amyloidose-Experte, dem Wissenschaftlichen Beirat seiner Tochtergesellschaft Nexcella beigetreten ist. Dr. Comenzo, Leiter des Myelom- und Amyloid-Programms am Tufts Medical Center, ist bekannt für seine Pionierarbeit bei der Entwicklung von Konsensrichtlinien für klinische Studien und Antwortkriterien bei AL-Amyloidose. Er war der Hauptautor der wegweisenden Ergebnisse der Andromeda-Studie, die zur ersten von der FDA genehmigten Therapie für AL-Amyloidose führten.
Dr. Comenzo äußerte seine Begeisterung, den Bemühungen von Nexcella, CAR-T NXC-201 zur Behandlung von rezidivierenden/refraktären AL-Amyloidose voranzubringen, beizutreten, einem Bereich ohne derzeit zugelassene Medikamente. Die Führung von Immix Biopharma ist überzeugt, dass Dr. Comenzos Expertise erheblichen Nutzen für ihre Forschungs- und Entwicklungsanstrengungen in diesem Bereich bringen wird.
- Addition of a renowned AL Amyloidosis expert to the Scientific Advisory Board
- Potential advancement in CAR-T therapy for relapsed/refractory AL Amyloidosis
- Access to expertise from a leader in developing clinical trial guidelines for AL Amyloidosis
- None.
- Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis
- Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis
LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq: IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medical Center, joined ImmixBio subsidiary Nexcella Scientific Advisory Board. Dr. Comenzo is internationally recognized for his pioneering work in developing consensus guidelines for clinical trials and response criteria in AL Amyloidosis, and was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis.
“CAR-T represents a novel approach to treat AL Amyloidosis. I am thrilled to see focus on developing treatment options for relapsed/refractory AL Amyloidosis, where no drugs are approved today. I am excited to join the Nexcella team’s efforts to advance CAR-T NXC-201," commented Dr. Comenzo.
"We are thrilled that Dr. Comenzo has joined our scientific advisory board. We believe we will benefit greatly from Dr. Comenzo’s counsel," stated Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Dr. Comenzo’s foundational contributions to the AL Amyloidosis field are internationally recognized. We are excited to be working with Dr. Comenzo.”
Dr. Comenzo is Director of the Myeloma and Amyloid Program; Director, the Cell Therapy Laboratory at Tufts Medical Center; and Professor of Medicine at Tufts University School of Medicine. He is principally responsible for the clinical care of all plasma cell disease patients and for clinical research for these diseases at Tufts Medical Center. Dr. Comenzo completed his residency at Boston City Hospital and his fellowship in hematology/oncology and transfusion medicine at Tufts Medical Center. Prior to coming to Tufts MC, Dr. Comenzo was medical director of the cell therapy laboratory, and an attending member at Memorial Sloan Kettering Cancer Center; a professor of medicine at Weil-Cornell School of Medicine; and an attending physician in hematology, the founder of the Stem Cell Transplant Program, and the director of the Blood Bank at Boston Medical Center. Dr. Comenzo is board certified in Internal Medicine and Hematology.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and immune-mediated diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2 trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity of any kind in AL Amyloidosis and short duration of cytokine release syndrome (CRS), supporting expansion into immune-mediated diseases. NXC-201 has been awarded Orphan Drug Designation (ODD) in AL Amyloidosis by the US FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
About Nexcella, Inc.
Nexcella, Inc. is a wholly-owned subsidiary of, and the cell therapy division of, Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX).
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, potential benefits of our product candidate CAR-T NXC-201. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1b/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the initial data initial data readouts, (ii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iii) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (iv) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (v) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2024 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
FAQ
Who is Dr. Raymond Comenzo and why is his joining Immix Biopharma (IMMX) significant?
What is Immix Biopharma (IMMX) developing for AL Amyloidosis treatment?
How might Dr. Comenzo's expertise benefit Immix Biopharma (IMMX)?
What is the current treatment landscape for relapsed/refractory AL Amyloidosis that Immix Biopharma (IMMX) is addressing?
